Prospects of Molecular Biotechnology in Diagnostics: Step Towards Precision Medicine

Sharma, Praveen; Dwivedi, Shailendra

doi:10.1007/s12291-017-0650-9

Cited by 15 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, not only limited to the above discussed studies, but other studies are also providing evidence that miRNAs play a crucial role in many of developmental processes and diseases. Although no single mechanism can be attributed to unravel their mode of action in various diseases, but consistent research at cellular level supported by robust bioinformatics can largely help decode mysteries of disease pathogenesis [6,7].…”

Section: Micro Rnas and Human Diseasesmentioning

confidence: 99%

MicroRNAs and Diseases: Promising Biomarkers for Diagnosis and Therapeutics

2019

Self Cite

View full text Add to dashboard Cite

Section: Micro Rnas and Human Diseasesmentioning

confidence: 99%

MicroRNAs and Diseases: Promising Biomarkers for Diagnosis and Therapeutics

2019

Self Cite

View full text Add to dashboard Cite

“…From this prospect, the availability of the complete human genome sequence has made it possible to analyse the influence of variations of the human genome sequence on the pathogenesis of significant diseases and the response to drug therapy at an accelerating rate in recent years. The fast build-up of knowledge on genome-disease and genome-drug interactions has also encouraged the transformation of pharmacogenetics into a new entity of human genetics, pharmacogenomics and, at the same time, provided a rationale for the hope that individualized medicine can be achieved in the near future [ 113 , 114 ].…”

Section: Personalized Medicine: An Integration Of Diagnostics With Thmentioning

confidence: 99%

Diseases and Molecular Diagnostics: A Step Closer to Precision Medicine

et al. 2017

Self Cite

View full text Add to dashboard Cite

The current advent of molecular technologies together with a multidisciplinary interplay of several fields led to the development of genomics, which concentrates on the detection of pathogenic events at the genome level. The structural and functional genomics approaches have now pinpointed the technical challenge in the exploration of disease-related genes and the recognition of their structural alterations or elucidation of gene function. Various promising technologies and diagnostic applications of structural genomics are currently preparing a large database of disease-genes, genetic alterations etc., by mutation scanning and DNA chip technology. Further the functional genomics also exploring the expression genetics (hybridization-, PCR-and sequence-based technologies), twohybrid technology, next generation sequencing with Bioinformatics and computational biology. Advances in microarray ''chip'' technology as microarrays have allowed the parallel analysis of gene expression patterns of thousands of genes simultaneously. Sequence information collected from the genomes of many individuals is leading to the rapid discovery of single nucleotide polymorphisms or SNPs. Further advances of genetic engineering have also revolutionized immunoassay biotechnology via engineering of antibody-encoding genes and the phage display technology. The Biotechnology plays an important role in the development of diagnostic assays in response to an outbreak or critical disease response need. However, there is also need to pinpoint various obstacles and issues related to the commercialization and widespread dispersal of genetic knowledge derived from the exploitation of the biotechnology industry and the development and marketing of diagnostic services. Implementation of genetic criteria for patient selection and individual assessment of the risks and benefits of treatment emerges as a major challenge to the pharmaceutical industry. Thus this field is revolutionizing current era and further it may open new vistas in the field of disease management.

show abstract

“…[18][19][20][21][22] Designs inspired by or mimicking the complexity of biological tissue have increased precision and personalization in both diagnostics and therapeutics. 23 Unfortunately, the unpredictable efficacy of nanomedicines in human patients related mainly to in vivo pharmacokinetics, tissue distribution, immunological responses, and penetration and accumulation at the target site have limited the clinical success of nanomedicines. [24][25][26] Biological barriers such as fluid dynamics within the blood, opsonization and recognition by the mononuclear phagocyte system, extravasation to the disease site, and intracellular compartmentalization all determine the in vivo fate of nanomedicines and thus must be considered in the design of novel formulations.…”

Section: Introductionmentioning

confidence: 99%